var data={"title":"Testicular sex cord stromal tumors","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Testicular sex cord stromal tumors</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/contributors\" class=\"contributor contributor_credentials\">Mary-Ellen Taplin, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/contributors\" class=\"contributor contributor_credentials\">Philip W Kantoff, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/contributors\" class=\"contributor contributor_credentials\">Michael E Ross, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Sep 27, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Sex cord stromal tumors (SCSTs) comprise approximately 5 percent of all testicular tumors, while the remainder are of germ cell origin [<a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/1\" class=\"abstract_t\">1</a>]. SCSTs, which arise from the supporting tissues of the testis, include Leydig, Sertoli, and granulosa cell tumors, as well as malignant mesothelioma of the tunica vaginalis, adenocarcinoma of the rete testis, and paratesticular rhabdomyosarcoma (<a href=\"image.htm?imageKey=ONC%2F115023\" class=\"graphic graphic_table graphicRef115023 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/2-5\" class=\"abstract_t\">2-5</a>]. In 2017, the World Health Organization (WHO) published a review and update of the classification of testicular non-germ cell tumors [<a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/6\" class=\"abstract_t\">6</a>].</p><p>The clinical presentation and management of SCSTs are discussed here. The pathology of SCSTs and an overview of testicular germ cell tumors are presented separately. (See <a href=\"topic.htm?path=anatomy-and-pathology-of-testicular-tumors#H20\" class=\"medical medical_review\">&quot;Anatomy and pathology of testicular tumors&quot;, section on 'Sex cord-stromal tumors'</a> and <a href=\"topic.htm?path=overview-of-the-treatment-of-testicular-germ-cell-tumors\" class=\"medical medical_review\">&quot;Overview of the treatment of testicular germ cell tumors&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">CLINICAL PRESENTATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The most common clinical presentation of testicular SCSTs is with a mass, which often causes swelling <span class=\"nowrap\">and/or</span> discomfort. Tumors may also be discovered on routine physical examination or during evaluation for endocrine symptoms due to sex hormone production [<a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/2,7\" class=\"abstract_t\">2,7</a>]. In general, there is a wide age range for SCSTs, with ages in two contemporary series ranging between 14 and 87 years [<a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/8,9\" class=\"abstract_t\">8,9</a>].</p><p>There are no known risk factors for SCSTs. Unlike germ cell tumors, there has been no definitive association with cryptorchidism, although such an association cannot be excluded [<a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/10,11\" class=\"abstract_t\">10,11</a>].</p><p>SCSTs do not typically produce markers such as lactate dehydrogenase (LDH), alpha-fetoprotein (AFP), and human chorionic gonadotropin (hCG), which are more commonly elevated in testicular germ cell tumors.</p><p>The clinical features of specific types of SCSTs are discussed in this section.</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Leydig cell tumors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Leydig cell tumors are the most common testicular SCSTs; in a series of 79,120 cases of testicular cancer in the National Cancer Database, 250 were malignant Leydig tumors (0.3 percent) [<a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/12\" class=\"abstract_t\">12</a>]. These tumors can present at any age, but they are most common in adults, with a median age in two series between 40 and 50 years [<a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/2,10\" class=\"abstract_t\">2,10</a>].</p><p>Leydig cells are the principal testicular source of androgens and are also capable of estrogen production. These tumors may produce either virilizing or feminizing symptoms [<a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/10\" class=\"abstract_t\">10</a>].</p><p>In adults, endocrine manifestations are found in 20 to 30 percent of cases, the most common of which is gynecomastia [<a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/1,13\" class=\"abstract_t\">1,13</a>]. Other symptoms can include loss of libido, erectile dysfunction, impotence, and infertility [<a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/10\" class=\"abstract_t\">10</a>]. (See <a href=\"topic.htm?path=clinical-features-diagnosis-and-evaluation-of-gynecomastia-in-adults\" class=\"medical medical_review\">&quot;Clinical features, diagnosis, and evaluation of gynecomastia in adults&quot;</a>.)</p><p>When Leydig cell tumors occur in children, precocious puberty is common [<a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/1\" class=\"abstract_t\">1</a>]. In boys with precocious puberty, Leydig cell tumor should be considered if asymmetric testicular enlargement is present. Even if a distinct mass cannot be palpated and is not detectable by ultrasonography, the larger testis should be biopsied if it enlarges during follow-up. (See <a href=\"topic.htm?path=definition-etiology-and-evaluation-of-precocious-puberty#H11\" class=\"medical medical_review\">&quot;Definition, etiology, and evaluation of precocious puberty&quot;, section on 'Boys'</a>.)</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Sertoli cell tumors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Sertoli cell tumors are classified as malignant Sertoli cell tumor (not otherwise specified), large cell calcifying Sertoli cell tumor, and intratubular large cell hyalinizing Sertoli cell tumor (linked with Peutz-Jeghers syndrome). (See <a href=\"topic.htm?path=anatomy-and-pathology-of-testicular-tumors#H22\" class=\"medical medical_review\">&quot;Anatomy and pathology of testicular tumors&quot;, section on 'Sertoli cell tumors'</a>.)</p><p>Sertoli cell tumors are less common than Leydig cell tumors, accounting for 0.1 percent of testicular tumors in a National Cancer Database analysis [<a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/12\" class=\"abstract_t\">12</a>]. Sertoli cell tumors can present at any age, with a reported mean of 45 years [<a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/3\" class=\"abstract_t\">3</a>]. However, patients with the large cell calcifying variant tend to be younger, with an average age at diagnosis of 21 years [<a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/14\" class=\"abstract_t\">14</a>]. Gynecomastia and other signs of hyperestrogenism are present in 20 to 30 percent of cases. In contrast to Leydig cell tumors, virilization is only rarely seen.</p><p>Sertoli cell testicular tumors have been associated with two inherited disorders, Peutz-Jeghers syndrome and Carney complex [<a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/15,16\" class=\"abstract_t\">15,16</a>]. (See <a href=\"topic.htm?path=peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Peutz-Jeghers syndrome: Epidemiology, clinical manifestations, and diagnosis&quot;</a> and <a href=\"topic.htm?path=cushings-syndrome-due-to-primary-pigmented-nodular-adrenocortical-disease#H5\" class=\"medical medical_review\">&quot;Cushing's syndrome due to primary pigmented nodular adrenocortical disease&quot;, section on 'Carney complex (CNC)'</a>.)</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Granulosa cell tumors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>These rare neoplasms are similar to their ovarian counterparts and are divided into adult and juvenile types. (See <a href=\"topic.htm?path=anatomy-and-pathology-of-testicular-tumors#H23\" class=\"medical medical_review\">&quot;Anatomy and pathology of testicular tumors&quot;, section on 'Granulosa cell tumors'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The adult type of granulosa cell tumor is very rare in the testis [<a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/17\" class=\"abstract_t\">17</a>]. The average age at presentation is 44 years, and approximately one-half of reported cases have associated gynecomastia [<a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/18,19\" class=\"abstract_t\">18,19</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The juvenile type of granulosa cell tumor is the most common testicular tumor of infancy and is only rarely seen in adults [<a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/20\" class=\"abstract_t\">20</a>]. These tumors have been associated with sex chromosome abnormalities, ambiguous genitalia, and ipsilateral cryptorchidism [<a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/21\" class=\"abstract_t\">21</a>]. They appear to be uniformly benign.</p><p/><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Other tumor types</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Other stromal tumors arising in the testis include malignant mesothelioma of the tunica vaginalis, paratesticular rhabdomyosarcoma, and adenocarcinoma of the rete testis. (See <a href=\"topic.htm?path=rhabdomyosarcoma-in-childhood-and-adolescence-epidemiology-pathology-and-molecular-pathogenesis\" class=\"medical medical_review\">&quot;Rhabdomyosarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">MANAGEMENT</span></p><p class=\"headingAnchor\" id=\"H1216077601\"><span class=\"h2\">Initial approach</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Radical inguinal orchiectomy is generally the procedure of choice for patients with suspected testicular cancer. Consideration can be given to partial orchiectomy; however, prospective data are not available to inform the decision between radical and partial resection, and radical resection remains the standard of care [<a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/22\" class=\"abstract_t\">22</a>]. The diagnostic classification of an SCST is based upon pathologic analysis of the surgical specimen. (See <a href=\"topic.htm?path=radical-inguinal-orchiectomy-for-testicular-germ-cell-tumors#H2\" class=\"medical medical_review\">&quot;Radical inguinal orchiectomy for testicular germ cell tumors&quot;, section on 'Surgical treatment of the testis'</a> and <a href=\"topic.htm?path=anatomy-and-pathology-of-testicular-tumors\" class=\"medical medical_review\">&quot;Anatomy and pathology of testicular tumors&quot;</a>.)</p><p>The favorable prognosis for patients with stage I disease is supported by an analysis of 315 patients with malignant Leydig or Sertoli cell tumors [<a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/12\" class=\"abstract_t\">12</a>]. Overall survival for stage I Leydig cell tumors was 98 and 91 percent at one and five years, respectively, and the overall survival for stage I Sertoli cell tumors was 93 and 77 percent at one and five years, respectively.</p><p>The favorable prognosis for patients with clinical stage I disease is also supported by two single-institution retrospective series. In one report, 38 men were successfully managed with excision of the primary tumor alone [<a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/23\" class=\"abstract_t\">23</a>]. At a median follow-up of seven years, none had developed metastatic disease. In another series of 48 men with short-term follow-up, the conclusion was that patients with one or no high-risk features can be safely observed without retroperitoneal lymph node dissection (RPLND). Early RPLND may be beneficial in those with two or more high-risk features or clinical stage IIa disease [<a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/24\" class=\"abstract_t\">24</a>].</p><p class=\"headingAnchor\" id=\"H3206123842\"><span class=\"h2\">Metastatic disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most SCSTs are benign. However, approximately 10 to 20 percent of tumors in adults can metastasize and ultimately result in death. After a patient has had an inguinal orchiectomy and the diagnosis of an SCST has been established, staging evaluation should include computed tomography (CT) of the chest, abdomen, and pelvis. The role of positron emission tomography (PET) scans in these tumors has not been defined. The presence of symptoms should determine whether other tests (eg, bone scan, neuroimaging) are indicated.</p><p>The risk for occult metastatic disease at the time of orchiectomy can be predicted from certain histologic features in the orchiectomy specimen [<a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/25\" class=\"abstract_t\">25</a>]. A retrospective analysis of 47 publications describing 292 patients (median follow-up 47 months), reported that the five-year occult metastatic disease-free survival was 98 percent in those with &lt;2 risk factors compared with 45 percent in those with &gt;2 risk factors. Risk factors included tumor &gt;5 cm, &gt;3 mitoses per high-powered field, positive margins, rete testis invasion, lymphovascular invasion, cellular atypia, and necrosis. These risk projections are limited due to the small size of the published series and the absence of central pathology review; however, they provide a guide to features of metastatic potential. In a patient with a tumor at high risk for occult disease, consideration can be given to more extensive imaging to define early metastasis, with consideration of early RPLND or metastasectomy. </p><p>RPLND has been used both in patients with established nodal disease and as a staging procedure to resect any microscopic disease [<a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/3,24,26\" class=\"abstract_t\">3,24,26</a>]. In a large single-institution series, 17 patients with SCSTs underwent RPLND [<a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/26\" class=\"abstract_t\">26</a>]. Among the nine with clinical stage I disease, retroperitoneal disease was not identified in any case, and all remained free of disease from 9 to 135 months after surgery. In the eight patients with clinical stage II or III disease, six died at 9 to 69 months after surgery, one was alive with disease at 13 months, and one was disease-free at eight months.</p><p>In patients with limited metastatic disease, metastasectomy should be considered because the response to chemotherapy and radiotherapy is generally poor. Radiation <span class=\"nowrap\">and/or</span> chemotherapy are reserved for palliation in patients with widespread unresectable disease, but response rates are low.</p><p>Active testicular germ cell regimens such as BEP (<a href=\"topic.htm?path=bleomycin-drug-information\" class=\"drug drug_general\">bleomycin</a>, <a href=\"topic.htm?path=etoposide-drug-information\" class=\"drug drug_general\">etoposide</a>, <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a>) or VIP (<a href=\"topic.htm?path=vinblastine-drug-information\" class=\"drug drug_general\">vinblastine</a>, <a href=\"topic.htm?path=ifosfamide-drug-information\" class=\"drug drug_general\">ifosfamide</a>, cisplatin) have been relatively ineffective, with only transient responses [<a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/2,26,27\" class=\"abstract_t\">2,26,27</a>]. The utility of newer agents, such as taxanes, <a href=\"topic.htm?path=gemcitabine-drug-information\" class=\"drug drug_general\">gemcitabine</a>, antiangiogenic agents, and tyrosine kinase inhibitors, and immunotherapy, such as programmed cell death 1 (PD-1) pathway inhibition, is unknown. To date, tumor gene profiling has not identified new therapeutic targets, but experience is limited, and tumor profiling can be considered, where available, in the context of experimental clinical trials.</p><p>Leydig cell tumors and adrenocortical cancers have common histologic and biochemical features. There have been case reports of palliative response to <a href=\"topic.htm?path=mitotane-drug-information\" class=\"drug drug_general\">mitotane</a> (o,p'DDD), an agent used in adrenocortical cancer [<a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/2,28,29\" class=\"abstract_t\">2,28,29</a>]. (See <a href=\"topic.htm?path=treatment-of-adrenocortical-carcinoma#H16810714\" class=\"medical medical_review\">&quot;Treatment of adrenocortical carcinoma&quot;, section on 'Mitotane monotherapy'</a>.)</p><p>The prognosis for patients with metastatic SCSTs is poor. Although prolonged survival has been reported, the median survival is between one and two years, and two-thirds of patients die within two years of developing metastases [<a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/2,10,30\" class=\"abstract_t\">2,10,30</a>].</p><p class=\"headingAnchor\" id=\"H1524981214\"><span class=\"h2\">Hypogonadism</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In men with Leydig, Sertoli, or granulosa cell tumors, assessment of the <span class=\"nowrap\">pituitary/gonadal</span> axis is recommended, with measurement of serum androgen, estrogen, and progesterone levels [<a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/3\" class=\"abstract_t\">3</a>]. If any of these hormones is elevated, it may be serially evaluated as a marker of tumor response to therapy.</p><p>The incidence of hypogonadism after orchiectomy appears to be higher in men with SCSTs than in those with germ cell tumors (42 versus 5 to 13 percent) [<a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/2,31\" class=\"abstract_t\">2,31</a>]. Thus, men with SCSTs are more likely to need <a href=\"topic.htm?path=testosterone-drug-information\" class=\"drug drug_general\">testosterone</a> replacement following surgery [<a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/2\" class=\"abstract_t\">2</a>]</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Sex cord stromal tumors (SCSTs) are rare testicular tumors that arise from the supporting tissues of the testis.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For all patients presenting with a testicular mass thought to be a testicular tumor, we recommend a radical inguinal orchiectomy to establish the histopathologic diagnosis and treat the primary tumor (<a href=\"grade.htm?i=3\" class=\"grade\">Grade 1C</a>). (See <a href=\"topic.htm?path=radical-inguinal-orchiectomy-for-testicular-germ-cell-tumors\" class=\"medical medical_review\">&quot;Radical inguinal orchiectomy for testicular germ cell tumors&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with Leydig, Sertoli, or granulosa cell tumors, we suggest staging for evidence of metastatic disease using computed tomography (CT) of the chest, abdomen, and pelvis and assessment of the <span class=\"nowrap\">pituitary/gonadal</span> axis with measurement of serum androgen, estrogen, and progesterone levels (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H7\" class=\"local\">'Management'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For patients with metastatic disease, we suggest surgical resection of all known sites of disease whenever possible (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H7\" class=\"local\">'Management'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>There is no established role for systemic therapy, and patients with nonresectable metastatic disease should be included in clinical studies whenever possible.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/1\" class=\"nounderline abstract_t\">Dilworth JP, Farrow GM, Oesterling JE. Non-germ cell tumors of testis. Urology 1991; 37:399.</a></li><li><a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/2\" class=\"nounderline abstract_t\">Conkey DS, Howard GC, Grigor KM, et al. Testicular sex cord-stromal tumours: the Edinburgh experience 1988-2002, and a review of the literature. Clin Oncol (R Coll Radiol) 2005; 17:322.</a></li><li class=\"breakAll\">Murthy V, Fisher C, Horwich A. Rare tumors of the testis and paratesticular tissues. In: Textbook of Uncommon Cancer, 3rd, Raghavan D, Brecher M, Johnson D, et al (Eds), Wiley, 2006. p.66.</li><li><a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/4\" class=\"nounderline abstract_t\">Schure PJ, van Dalen KC, Ruitenberg HM, van Dalen T. Mesothelioma of the tunica vaginalis testis: a rare malignancy mimicking more common inguino-scrotal masses. J Surg Oncol 2006; 94:162.</a></li><li><a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/5\" class=\"nounderline abstract_t\">Plas E, Riedl CR, Pfl&uuml;ger H. Malignant mesothelioma of the tunica vaginalis testis: review of the literature and assessment of prognostic parameters. Cancer 1998; 83:2437.</a></li><li><a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/6\" class=\"nounderline abstract_t\">Idrees MT, Ulbright TM, Oliva E, et al. The World Health Organization 2016 classification of testicular non-germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel. Histopathology 2017; 70:513.</a></li><li><a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/7\" class=\"nounderline abstract_t\">Anderson MS, Brogi E, Biller BM. Occult Leydig cell tumor in a patient with gynecomastia. Endocr Pract 2001; 7:267.</a></li><li><a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/8\" class=\"nounderline abstract_t\">Cornejo KM, Young RH. Adult granulosa cell tumors of the testis: a report of 32 cases. Am J Surg Pathol 2014; 38:1242.</a></li><li><a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/9\" class=\"nounderline abstract_t\">Kao CS, Kum JB, Idrees MT, Ulbright TM. Sclerosing Sertoli cell tumor of the testis: a clinicopathologic study of 20 cases. Am J Surg Pathol 2014; 38:510.</a></li><li><a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/10\" class=\"nounderline abstract_t\">Al-Agha OM, Axiotis CA. An in-depth look at Leydig cell tumor of the testis. Arch Pathol Lab Med 2007; 131:311.</a></li><li><a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/11\" class=\"nounderline abstract_t\">Kim I, Young RH, Scully RE. Leydig cell tumors of the testis. A clinicopathological analysis of 40 cases and review of the literature. Am J Surg Pathol 1985; 9:177.</a></li><li><a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/12\" class=\"nounderline abstract_t\">Banerji JS, Odem-Davis K, Wolff EM, et al. Patterns of Care and Survival Outcomes for Malignant Sex Cord Stromal Testicular Cancer: Results from the National Cancer Data Base. J Urol 2016; 196:1117.</a></li><li><a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/13\" class=\"nounderline abstract_t\">Gabrilove JL, Nicolis GL, Mitty HA, Sohval AR. Feminizing interstitial cell tumor of the testis: personal observations and a review of the literature. Cancer 1975; 35:1184.</a></li><li class=\"breakAll\">Ulbright TM, Amin MB, Young RH. Ulbright TM, Amin MB, Young RH. In: Atlas of Tumor Pathology, 3rd, Rosai J, Sobin LH (Eds), Armed Forces Institute of Pathology, Washington, DC 1999.</li><li><a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/15\" class=\"nounderline abstract_t\">Proppe KH, Scully RE. Large-cell calcifying Sertoli cell tumor of the testis. Am J Clin Pathol 1980; 74:607.</a></li><li><a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/16\" class=\"nounderline abstract_t\">Washecka R, Dresner MI, Honda SA. Testicular tumors in Carney's complex. J Urol 2002; 167:1299.</a></li><li><a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/17\" class=\"nounderline abstract_t\">Ditonno P, Lucarelli G, Battaglia M, et al. Testicular granulosa cell tumor of adult type: a new case and a review of the literature. Urol Oncol 2007; 25:322.</a></li><li><a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/18\" class=\"nounderline abstract_t\">Al-Bozom IA, El-Faqih SR, Hassan SH, et al. Granulosa cell tumor of the adult type: a case report and review of the literature of a very rare testicular tumor. Arch Pathol Lab Med 2000; 124:1525.</a></li><li><a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/19\" class=\"nounderline abstract_t\">Arzola J, Hutton RL, Baughman SM, Mora RV. Adult-type testicular granulosa cell tumor: case report and review of the literature. Urology 2006; 68:1121.e13.</a></li><li><a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/20\" class=\"nounderline abstract_t\">Garrett JE, Cartwright PC, Snow BW, Coffin CM. Cystic testicular lesions in the pediatric population. J Urol 2000; 163:928.</a></li><li><a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/21\" class=\"nounderline abstract_t\">Gourlay WA, Johnson HW, Pantzar JT, et al. Gonadal tumors in disorders of sexual differentiation. Urology 1994; 43:537.</a></li><li><a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/22\" class=\"nounderline abstract_t\">Nicolai N, Necchi A, Raggi D, et al. Clinical outcome in testicular sex cord stromal tumors: testis sparing vs. radical orchiectomy and management of advanced disease. Urology 2015; 85:402.</a></li><li><a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/23\" class=\"nounderline abstract_t\">Featherstone JM, Fernando HS, Theaker JM, et al. Sex cord stromal testicular tumors: a clinical series--uniformly stage I disease. J Urol 2009; 181:2090.</a></li><li><a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/24\" class=\"nounderline abstract_t\">Silberstein JL, Bazzi WM, Vertosick E, et al. Clinical outcomes of local and metastatic testicular sex cord-stromal tumors. J Urol 2014; 192:415.</a></li><li><a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/25\" class=\"nounderline abstract_t\">Rove KO, Maroni PD, Cost CR, et al. Pathologic Risk Factors for Metastatic Disease in Postpubertal Patients With Clinical Stage I Testicular Stromal Tumors. Urology 2016; 97:138.</a></li><li><a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/26\" class=\"nounderline abstract_t\">Mosharafa AA, Foster RS, Bihrle R, et al. Does retroperitoneal lymph node dissection have a curative role for patients with sex cord-stromal testicular tumors? Cancer 2003; 98:753.</a></li><li><a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/27\" class=\"nounderline abstract_t\">Farkas LM, Sz&eacute;kely JG, Pusztai C, Baki M. High frequency of metastatic Leydig cell testicular tumours. Oncology 2000; 59:118.</a></li><li><a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/28\" class=\"nounderline abstract_t\">Azer PC, Braunstein GD. Malignant Leydig cell tumor: objective tumor response to o,p'-DDD. Cancer 1981; 47:1251.</a></li><li><a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/29\" class=\"nounderline abstract_t\">van der Hem KG, Boven E, van Hennik MB, Pinedo HM. Malignant Leydig cell tumor of the testis in complete remission on o,p'-dichlorodiphenyl-dichloroethane. J Urol 1992; 148:1256.</a></li><li><a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/30\" class=\"nounderline abstract_t\">Grem JL, Robins HI, Wilson KS, et al. Metastatic Leydig cell tumor of the testis. Report of three cases and review of the literature. Cancer 1986; 58:2116.</a></li><li><a href=\"https://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors/abstract/31\" class=\"nounderline abstract_t\">Hansen PV, Trykker H, Andersen J, Helkjaer PE. Germ cell function and hormonal status in patients with testicular cancer. Cancer 1989; 64:956.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 2972 Version 11.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H8\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">CLINICAL PRESENTATION</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Leydig cell tumors</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Sertoli cell tumors</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Granulosa cell tumors</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Other tumor types</a></li></ul></li><li><a href=\"#H7\" id=\"outline-link-H7\">MANAGEMENT</a><ul><li><a href=\"#H1216077601\" id=\"outline-link-H1216077601\">Initial approach</a></li><li><a href=\"#H3206123842\" id=\"outline-link-H3206123842\">Metastatic disease</a></li><li><a href=\"#H1524981214\" id=\"outline-link-H1524981214\">Hypogonadism</a></li></ul></li><li><a href=\"#H8\" id=\"outline-link-H8\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ONC/2972|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/115023\" class=\"graphic graphic_table\">- WHO 2016 classification of non-germ cell tumors of the testis</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=anatomy-and-pathology-of-testicular-tumors\" class=\"medical medical_review\">Anatomy and pathology of testicular tumors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-diagnosis-and-evaluation-of-gynecomastia-in-adults\" class=\"medical medical_review\">Clinical features, diagnosis, and evaluation of gynecomastia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cushings-syndrome-due-to-primary-pigmented-nodular-adrenocortical-disease\" class=\"medical medical_review\">Cushing's syndrome due to primary pigmented nodular adrenocortical disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=definition-etiology-and-evaluation-of-precocious-puberty\" class=\"medical medical_review\">Definition, etiology, and evaluation of precocious puberty</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-treatment-of-testicular-germ-cell-tumors\" class=\"medical medical_review\">Overview of the treatment of testicular germ cell tumors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Peutz-Jeghers syndrome: Epidemiology, clinical manifestations, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=radical-inguinal-orchiectomy-for-testicular-germ-cell-tumors\" class=\"medical medical_review\">Radical inguinal orchiectomy for testicular germ cell tumors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=rhabdomyosarcoma-in-childhood-and-adolescence-epidemiology-pathology-and-molecular-pathogenesis\" class=\"medical medical_review\">Rhabdomyosarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-adrenocortical-carcinoma\" class=\"medical medical_review\">Treatment of adrenocortical carcinoma</a></li></ul></div></div>","javascript":null}